How Does Lannett Company Company's Operating Model Create Value?

Lannett Company's core product set targets non-opioid ADHD formulations and sterile injectable drugs produced at a 425,000 square foot cGMP facility with about 3.6 billion tablets annual tablet capacity. The focus is on formulations with higher regulatory barriers versus plain oral solids.

Customers - wholesalers, hospital systems, and global firms - need dependable US-based supply to avoid import risk and tariffs, plus partners require products that clear complex FDA pathways. Lannett's sterile lines and controlled-substance approvals reduce disruption risk for buyers.

The value proposition rests on regulatory complexity as a barrier to entry, enabling pricing power and long-term contracts; customers pay for reliability and compliance. This drives Lannett company value creation through lower volatility in volumes and higher mix of specialty SKUs.

Choosing controlled substances and liquid/sterile formulations signals a strategy of vertical integration and supply-chain sovereignty: prioritize US manufacturing scale, quality control, and regulatory capability over low-margin commoditized generics. This aligns with Lannett manufacturing strategy and Lannett supply chain management goals.

Lannett operating model centers on selling selective, higher-margin generic molecules where limited competition preserves Average Selling Prices versus commoditized categories. TTM FY 2025 revenues were approximately $306,000,000, reflecting a stabilized revenue base after restructuring and focused SKU mix.

The Lannett business model monetizes formulation and controlled-substance expertise through a contract development and manufacturing organization (CDMO), which represents roughly 10% of organizational value by charging service fees for high-potency and DEA-controlled products.

Lannett pricing strategy for generic drugs uses tiered ASPs-premium pricing for limited-competition molecules and fee-for-service for CDMO work-reducing exposure to the typical 8-10% annual price erosion in commoditized categories and stabilizing margins.

Value capture peaks where Lannett manufacturing strategy meets market gaps: specialized production for controlled substances, and strategic asset valuation realized in the 2025 Aurobindo acquisition where reshoring-domestic production to avoid tariffs and procurement barriers-was priced into a $250,000,000 valuation. See Governance Structure of Lannett Company Company for governance context: Governance Structure of Lannett Company Company

Maintaining a US-based, FDA- and DEA-compliant facility delivers predictable supply to domestic customers and reduces U.S. import risk; that reliability is a core Lannett operating model advantage. In 2025 the facility's compliance record supported higher contract win rates with hospital and government buyers.

Focus on oral solids and niche generics created operational focus and streamlined quality control processes, improving throughput and reducing batch-release delays-key elements of Lannett manufacturing strategy. Integration into Aurobindo in 2025 improved purchasing scale and shortened lead times.

As a standalone, low production scale left Lannett vulnerable to rapid price deflation in retail generics; some oral solids fell below $1.50 per 30-day supply in the US market, squeezing margins and EBITDA. Concentration in low-price SKUs amplified revenue volatility and limited bargaining power with large buyers.

Post-acquisition, the model looks more durable: Aurobindo's scale mitigates the prior scale weakness, turning Lannett Company value creation into an EBITDA-positive domestic hub by 2026. Supply chain resilience and onshore compliance support sustained demand from US institutional buyers, though margin upside depends on integration synergies and portfolio rationalization.